The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy

Human epidermal growth factor receptor 2 (HER2) is a clinically validated target for breast cancer therapy. Previously, a drug-fused HER2-targeting affinity protein construct successfully extended the survival of mice bearing HER2-expressing xenografts. The aim of this study was to evaluate the infl...

Cijeli opis

Bibliografski detalji

Glavni autori:	Wen Yin, Tianqi Xu, Mohamed Altai, Maryam Oroujeni, Jie Zhang, Anzhelika Vorobyeva, Olga Vorontsova, Sergey V. Vtorushin, Vladimir Tolmachev, Torbjörn Gräslund, Anna Orlova
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2021-11-01
Serija:	Pharmaceutics
Teme:	HER2 affibody molecule albumin-binding domain drug conjugate targeted therapy mertansine
Online pristup:	https://www.mdpi.com/1999-4923/13/11/1974
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!